Amgen melanoma drug shrinks tumors but fails secondary study goal

April 4 (Reuters) - Amgen Inc said its experimental drug to treat a deadly form of skin cancer shrank tumors, but did not significantly improve overall survival rates in patients enrolled in a late-stage study.